Please login to the form below

Not currently logged in

Bristol Myers Squibb

This page shows the latest Bristol Myers Squibb news and features for those working in and with pharma, biotech and healthcare.

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

This included approvals for not only Keytruda, but also Roche’s Tecentriq (atezolizumab) and Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in a number of cancer types.

Latest news

More from news
Approximately 177 fully matching, plus 937 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 4 fully matching, plus 50 partially matching documents found.

Latest appointments

More from appointments
Approximately 10 fully matching, plus 105 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...